A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA

CompletedOBSERVATIONAL
Enrollment

134

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Symptomatic Vitreomacular Adhesion (VMA)
Trial Locations (24)

10021

MaculaCare, New York

19107

Wills Eye Institute, Philadelphia

26506

West Virginia University Eye Institute, Morgantown

27710

Duke University Eye Center, Durham

30060

Marietta Eye Clinic, Marietta

33711

Retina Vitreous Associates of Florida, St. Petersburg

37660

Southeastern Retina Associates, P.C., Kingsport

42001

Carl W. Baker, Paducah

57701

Black Hills Regional Eye Institute, Rapid City

60612

Rush university medical center-Dept ophthalmology, Chicago

61801

Carle Foundation Hospital, Urbana

66211

Sabates Eye Centers, Leawood

75075

Retina Specialists, Plano

77030

Retina Consultants of Houston, Houston

78503

Valley Retina Institute, PA, McAllen

84107

Retina Associates of Utah, P.C., Salt Lake City

89502

Sierra Eye Associates, Reno

92037

Scripps Clinic, La Jolla

92705

Orange County Retina Medical Group, Santa Ana

93103

California Retina Consultants, Santa Barbara

95008

Retinal Diagnostic Center, Campbell

02114

Ophthalmic Consultants of Boston, Boston

02215

Harvard Vanguard Medical Associates, Boston

03801

Eyesight Ophthalmic Services, Portsmouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ThromboGenics

INDUSTRY

NCT02193945 - A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA | Biotech Hunter | Biotech Hunter